Inventor
EKKEHARD MOESSNER
Inventor
CH
Overview
Patents· 43 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides32%
A61KPreparations for medical, dental or toiletry purposes30%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations30%
C12NMicroorganisms or enzymes5%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
C40BCombinatorial chemistry2%
PatentTitleYear
12,590,151Anti-human CD19 antibodies with high affinity202612,473,373Bispecific antibody molecules binding to CD3 and EGFRvIII202512,466,889Anti-HLA-G antibodies and use thereof202512,441,812Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules202512,331,134Trispecific antibodies specific for HER2 and a blood brain barrier receptor and methods of use202512,297,263Humanized anti-Tau(PS422) antibodies and methods of use202512,291,561Antigen binding receptors specific for mutated Fc domains202512,286,486Anti-FAP antibodies and methods of use202512,258,371Stabilized immunoglobulin domains202512,215,152Humanized anti-human CD19 antibodies and methods of use202512,215,155Antibodies binding to CD3 and CD19202512,202,870Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof202512,139,553T cell activating bispecific antigen binding molecules202412,129,306Antibodies binding to STEAP-1202412,103,982T cell activating bispecific antigen binding molecules202412,098,213Antibodies binding to HLA-A2/WT1202412,038,441CAR-T reporter based diagnostic assays to detect tumor antigens in cancer patients202412,000,064Universal reporter cell assay for specificity test of novel antigen binding moieties202411,993,642Trivalent, bispecific antibodies202411,952,421Bispecific antibodies against CD3EPSILON and ROR1202411,787,873Bispecific HER2 antibodies and methods of use202311,788,205Car-t cell assay for specificity test of novel antigen binding moieties202311,780,920Antibodies binding to CD3 and CD19202311,780,919Bispecific antigen binding molecules targeting OX40 and FAP202311,685,790Antibodies binding to STEAP-1202311,679,127Antigen binding receptors specific for mutated Fc domains202311,672,858Bispecific antibody molecules binding to CD3 and TYRP-1202311,608,376Tumor-targeted agonistic CD28 antigen binding molecules202311,591,397Bispecific antibody molecules binding to CD3 and EGFRvIII202311,583,575MHC-bound peptide arrays and methods of use thereof202311,572,404Humanized anti-Tau(pS422) antibodies and methods of use202311,525,007Antibody fab and Fc variants202211,459,404Bispecific T cell activating antigen binding molecules202211,440,971Fc-region variants with modified FcRn-binding and methods of use202211,365,232Interleukin-2 fusion proteins and uses thereof202211,332,545Anti-FAP antibodies and methods of use202211,306,154Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer202211,286,300Humanized anti-human CD19 antibodies and methods of use202211,267,903Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimer202211,214,622Antibodies specific for DR5 and methods of use202211,192,957Antibodies binding to HLA-A2/WT1202111,180,571Antibodies binding to STEAP-1202111,149,083Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moiety2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to HOFFMANN LA ROCHE (37)· patent assignee history
2021Patents assigned to HOFFMANN—LA ROCHE INC (1)· patent assignee history
2021–2026Based in CH· patent location history
2022–2025Patents assigned to ROCHE GLYCART AG (5)· patent assignee history
2023Patents assigned to HOFFMAN LA ROCHER INC (1)· patent assignee history
2024Patents assigned to BRISTOL MYERS SQUIBB CO (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| HOFFMANN LA ROCHE | 37 | 2021–2026 |
| ROCHE GLYCART AG | 5 | 2022–2025 |
| BRISTOL MYERS SQUIBB CO | 1 | 2024 |
| HOFFMAN LA ROCHER INC | 1 | 2023 |
| HOFFMANN—LA ROCHE INC | 1 | 2021 |
Locations
| Location | Patents | Span |
|---|---|---|
| CH | 43 | 2021–2026 |